Retour
NICOX (EPA:COX) Nicox Announces the Publication in Leading Scientific Journal of Pre-Clinical Efficacy Results on a New Class of Non-PGA NO-donating IOP-Lowering Compounds
Directive transparence : information réglementée
23/02/2021 07:30
Tweeter
23/02/2021 07:30
Nicox Announces the Publication in Leading Scientific Journal of...
09/02/2021 07:30
Bausch Health Announces Vyzulta® (latanoprostene Bunod Ophthalmic...
21/01/2021 09:46
Nicox (COX): Initiation - Focus on sight
06/01/2021 07:30
Nicox’s Licensee Bausch + Lomb Launches VYZULTA in Mexico
22/12/2020 07:30
Nicox’s Licensee Bausch + Lomb Secures Approval of VYZULTA in Colombia
04/12/2020 07:30
Nicox Raises €15 million in Private Placement
25/11/2020 08:00
Nicox Analyst Coverage Initiated by Kepler Cheuvreux
05/08/2020 09:15
Nicox Negotiating €2 million Non-Dilutive Loans Guaranteed by the French...
05/08/2020 07:30
Nicox: Implementation of a liquidity contract with Kepler Cheuvreux
15/07/2020 07:30
Nicox Reports on Enrollment Progress in Mont Blanc Phase 3 Clinical Trial...
Voir tous les communiqués de NICOX